Journal of Hepatology
Volume 49, Issue 4 , Pages 625-633 , October 2008

Acute hepatitis C: Current status and remaining challenges

  • Teresa Santantonio

      Affiliations

    • Clinic of Infectious Diseases, University of Bari, Policlinico, Piazza G. Cesare 11, 70124 Bari, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +390805478237; fax: +390805478333.
    • Address: Internal Medicine, Immunology and Infectious Diseases, Piazza G. Cesare 11, Bari 70124, Italy.
    • ,
  • Johannes Wiegand

      Affiliations

    • Department of Internal Medicine II, University of Leipzig, Philipp-Rosenthal-Strasse 27, 04103 Leipzig, Germany
    • Department of Gastroenterology, Hepatology, and Endocrinology, Hannover Medical School, Hannover, Germany
    • ,
  • J. Tilman Gerlach

      Affiliations

    • Department of Gastroenterology and Hepatology, University of Zurich, Rämistrasse 100, 8091 Zurich, Switzerland
    • Department of Gastroenterology and Hepatology, Kantonsspital St. Gallen, Rorschacherstrasse 95, 9007 St. Gallen, Switzerland

  • Image Result

    Sustained virological response rates among patients with acute hepatitis C who received standard or induction doses of conventional interferon alfa-2b (IFN alfa-2b) . Studies of Poynard [42], Cammà [4

    Sustained virological response rates among patients with acute hepatitis C who received standard or induction doses of conventional interferon alfa-2b (IFN alfa-2b) . Studies of Poynard [42], Cammà [41], and Licata [43] are meta-analyses that included at least one study of interferon-beta. Data from Licata et al. [43] include one study of induction therapy (Jaeckel et al. [44]) and represent the risk difference for attaining undetectable HCV RNA versus no treatment. ALT, alanine aminotransferase; HLB IFN, human lymphoblastoid interferon.

  • Image Result
    Sustained virological response (SVR) among patients with acute hepatitis C who received pegylated interferon alfa-2b for 12 or 24 weeks. Data from Kamal et al. [17] were derived from separate treatmen

    Sustained virological response (SVR) among patients with acute hepatitis C who received pegylated interferon alfa-2b for 12 or 24 weeks. Data from Kamal et al. [17] were derived from separate treatment arms in the same study.

☆ The authors declare that they do not have anything to disclose regarding funding from industries or conflict of interest with respect to this manuscript.

PII: S0168-8278(08)00434-0

doi: 10.1016/j.jhep.2008.07.005

Journal of Hepatology
Volume 49, Issue 4 , Pages 625-633 , October 2008

Article Tools

* Image Usage & Resolution